AMRN vs GSK
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Aug 01, 2026
AMRN
GSK
Investment Advisor Scores
GSK
AI Analyst Insights
Detailed Metrics Comparison
| Metric | AMRN | GSK | Winner |
|---|---|---|---|
|
Valuation
Lower P/E and PEG ratios suggest a stock may be undervalued relative to earnings and growth. Value investors prefer lower multiples. |
|||
| Forward P/E | 500 | 22.1729 | GSK |
| PEG Ratio | 0.8093 | 19.9551 | AMRN |
|
Growth
Higher revenue and earnings growth rates indicate a company is expanding faster. Strong growth often justifies premium valuations. |
|||
| Revenue Growth | -42.0% | 5.3% | GSK |
| Earnings Growth | -94.2% | -69.5% | GSK |
|
Quality & Profitability
Higher Tradestie Score and profit margins reveal how efficiently a company operates. Strong profitability indicates competitive advantages. |
|||
| Tradestie Score | 49.6/100 | 48.7/100 | AMRN |
| Profit Margin | -14.6% | 14.5% | GSK |
|
Risk Profile
Lower Beta and Implied Volatility values indicate reduced market risk. Conservative investors favor stocks with less price volatility. |
|||
| Beta | 1.00 | 1.00 | Tie |
|
Sentiment
AI Recommendation reflects overall analyst and proprietary sentiment. Stronger recommendations signal higher conviction. |
|||
| AI Recommendation | HOLD | HOLD | Tie |
Relative Price Performance (Last 90 Days)
Current Technical Phase
AMRN
MarkdownPrice below a falling SMA50 (slope -0.6%), weak momentum, RSI 44
GSK
DistributionPrice near a flattening SMA50 (slope 0.3%) with fading momentum, RSI 48
Fundamentals Snapshot
| Metric | AMRN | GSK |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | -235.7 | 10.0 |
| Trailing P/E | — | 16.4 |
| Revenue (TTM) | — | — |
| Revenue Growth | -0.4% | 0.1% |
| Gross Margin | 0.4% | 0.7% |
| Operating Margin | -0.3% | 0.3% |
| EPS | -1.20 | 3.15 |
| Dividend Yield | — | 0.04% |